دورية أكاديمية
أعرض في EDS

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.

التفاصيل البيبلوغرافية
العنوان: CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.
المؤلفون: Muniz TP; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, University Health Network, Toronto, ON M5S 1Z5, Canada., Araujo DV; Hospital de Base, Faculdade de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto 15090-000, Brazil., Savage KJ; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC V5Z 1M9, Canada., Cheng T; Department of Oncology, University of Calgary, Calgary, AB T2N 4N2, Canada., Saha M; Division of Endocrinology and Metabolism, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada., Song X; The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada., Gill S; Division of Endocrinology and Metabolism, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada., Monzon JG; Department of Oncology, University of Calgary, Calgary, AB T2N 4N2, Canada., Grenier D; Department of Medical Oncology, University of Manitoba, Winnipeg, MB R3A 1R9, Canada., Genta S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, University Health Network, Toronto, ON M5S 1Z5, Canada., Allen MJ; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, University Health Network, Toronto, ON M5S 1Z5, Canada., Arteaga DP; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, University Health Network, Toronto, ON M5S 1Z5, Canada., Saibil SD; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, University Health Network, Toronto, ON M5S 1Z5, Canada., Butler MO; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, University Health Network, Toronto, ON M5S 1Z5, Canada., Spreafico A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, University Health Network, Toronto, ON M5S 1Z5, Canada., Hogg D; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, University Health Network, Toronto, ON M5S 1Z5, Canada.
المصدر: Cancers [Cancers (Basel)] 2021 Dec 24; Vol. 14 (1). Date of Electronic Publication: 2021 Dec 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Immune checkpoint inhibitor (ICI)-induced insulin-dependent diabetes mellitus (IDDM) is a rare but potentially fatal immune-related adverse event (irAE). In this multicentre retrospective cohort study, we describe the characteristics of ICI-induced IDDM in patients treated across five Canadian cancer centres, as well as their tumor response rates and survival. In 34 patients identified, 25 (74%) were male and 19 (56%) had melanoma. All patients received anti-programed death 1 (anti-PD1) or anti-programmed death ligand-1 (anti-PD-L1)-based therapy. From ICI initiation, median time to onset of IDDM was 2.4 months (95% CI 1.1-3.6). Patients treated with anti-PD1/PD-L1 in combination with an anti-cytotoxic T lymphocyte antigen 4 antibody developed IDDM earlier compared with patients on monotherapy (1.4 vs. 3.9 months, p = 0.05). Diabetic ketoacidosis occurred in 21 (62%) patients. Amongst 30 patients evaluable for response, 10 (33%) had a complete response and another 10 (33%) had a partial response. Median overall survival was not reached (95% CI NE; median follow-up 31.7 months). All patients remained insulin-dependent at the end of follow-up. We observed that ICI-induced IDDM is an irreversible irAE and may be associated with a high response rate and prolonged survival.
References: N Engl J Med. 2020 Dec 3;383(23):2207-2218. (PMID: 33264544)
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. (PMID: 29442540)
Mol Cell. 2021 Jun 3;81(11):2317-2331.e6. (PMID: 33909988)
J Immunother Cancer. 2019 Nov 15;7(1):306. (PMID: 31730012)
Cancers (Basel). 2020 Oct 15;12(10):. (PMID: 33076303)
N Engl J Med. 2020 Sep 24;383(13):1218-1230. (PMID: 32945632)
J Immunother Cancer. 2017 Nov 21;5(1):95. (PMID: 29162153)
N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431)
Diabetes Res Clin Pract. 2020 Apr;162:108115. (PMID: 32179128)
Diabetes Care. 2021 Jan;44(Suppl 1):S211-S220. (PMID: 33298426)
Cancer Discov. 2022 Jan;12(1):90-107. (PMID: 34789537)
Clin Exp Immunol. 2020 May;200(2):131-140. (PMID: 32027018)
EBioMedicine. 2018 Oct;36:367-375. (PMID: 30269996)
Diabetes Care. 2019 Sep;42(9):e153-e154. (PMID: 31308021)
Diabetes Care. 2018 Dec;41(12):e150-e151. (PMID: 30305348)
Nat Commun. 2021 Mar 4;12(1):1439. (PMID: 33664251)
Diabetes Care. 2020 Jan;43(1):e10. (PMID: 31862826)
J Diabetes. 2015 Jan;7(1):68-73. (PMID: 25695113)
JAMA Oncol. 2018 Feb 1;4(2):173-182. (PMID: 28973656)
BMJ Open Diabetes Res Care. 2019 Feb 13;7(1):e000591. (PMID: 30899528)
N Engl J Med. 2018 Nov 22;379(21):2040-2051. (PMID: 30280635)
Curr Opin Endocrinol Diabetes Obes. 2020 Aug;27(4):187-193. (PMID: 32618630)
Diabetes Care. 2014;37(1):9-16. (PMID: 24356592)
Diabetes Metab Res Rev. 2011 Nov;27(8):959-64. (PMID: 22069293)
Genes (Basel). 2019 Sep 13;10(9):. (PMID: 31540313)
Diabetol Int. 2018 Jul 3;10(1):58-66. (PMID: 30800564)
N Engl J Med. 2019 Mar 21;380(12):1116-1127. (PMID: 30779529)
Aliment Pharmacol Ther. 2019 Oct;50(8):885-900. (PMID: 31518029)
Acta Diabetol. 2019 Apr;56(4):441-448. (PMID: 30284618)
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33. (PMID: 33298413)
Diabetes Care. 2020 Jul;43(7):e79-e80. (PMID: 32393586)
Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945)
Curr Diab Rep. 2019 Nov 21;19(12):141. (PMID: 31754894)
Endocr Rev. 2019 Feb 1;40(1):17-65. (PMID: 30184160)
N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856)
J Clin Oncol. 2015 Mar 1;33(7):773-81. (PMID: 25605840)
Diabetes. 2018 Aug;67(8):1471-1480. (PMID: 29937434)
Maturitas. 2020 Jul;137:37-44. (PMID: 32498935)
Diabetes Care. 2009 Jul;32(7):1335-43. (PMID: 19564476)
Diabet Med. 2019 Sep;36(9):1075-1081. (PMID: 31199005)
Diabetologia. 2007 Nov;50(11):2239-44. (PMID: 17851648)
Diabetes Res Clin Pract. 2019 Mar;149:9-17. (PMID: 30710658)
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. (PMID: 33298420)
Melanoma Res. 2019 Jun;29(3):328-332. (PMID: 30817442)
Genes Immun. 2014 Apr;15(4):210-7. (PMID: 24598797)
Lancet. 2021 Jul 3;398(10294):27-40. (PMID: 34102137)
فهرسة مساهمة: Keywords: anti-CTLA4; anti-PD-L1; anti-PD1; diabetes mellitus; immune checkpoint inhibitor; immune-related adverse event; survival
تواريخ الأحداث: Date Created: 20220111 Latest Revision: 20220114
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8750429
DOI: 10.3390/cancers14010089
PMID: 35008256
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers14010089